These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 31476489

  • 1. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H, Kim D, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Hwang S, Kim KH, Song GW, Ahn CS, Lee JH, Hwang DW, Kim SC, Jang SJ, Hong SM, Kim TW, Ryoo BY.
    Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
    [Abstract] [Full Text] [Related]

  • 2. Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer.
    Kim H, Kim JY, Park KU.
    Oncology; 2023 Oct; 101(1):41-48. PubMed ID: 36257294
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.
    Simbolo M, Fassan M, Ruzzenente A, Mafficini A, Wood LD, Corbo V, Melisi D, Malleo G, Vicentini C, Malpeli G, Antonello D, Sperandio N, Capelli P, Tomezzoli A, Iacono C, Lawlor RT, Bassi C, Hruban RH, Guglielmi A, Tortora G, de Braud F, Scarpa A.
    Oncotarget; 2014 May 15; 5(9):2839-52. PubMed ID: 24867389
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing.
    Putra J, de Abreu FB, Peterson JD, Pipas JM, Mody K, Amos CI, Tsongalis GJ, Suriawinata AA.
    Exp Mol Pathol; 2015 Oct 15; 99(2):240-4. PubMed ID: 26189129
    [Abstract] [Full Text] [Related]

  • 9. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R, Li Q, Fu J, Jin Z, Su J, Zhang J, Chen C, Geng Z, Zhang D.
    BMC Cancer; 2021 Feb 03; 21(1):112. PubMed ID: 33535978
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, Nasti G, Montano M, Amatu A, Aprile G, Cagnazzo C, Fasola G, Siena S, Ciuffreda L, Reni M, Aglietta M.
    Cancer; 2016 Feb 15; 122(4):574-81. PubMed ID: 26540314
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.
    Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM, Ciombor K, Wu C, Shroff RT, Chen JL, Bekaii-Saab T.
    Cancer; 2016 Dec 01; 122(23):3657-3666. PubMed ID: 27495988
    [Abstract] [Full Text] [Related]

  • 15. Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer.
    Yu H, Xu Y, Gao W, Li M, He J, Deng X, Xing W.
    Front Oncol; 2022 Dec 01; 12():930611. PubMed ID: 36072793
    [Abstract] [Full Text] [Related]

  • 16. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.
    Wardell CP, Fujita M, Yamada T, Simbolo M, Fassan M, Karlic R, Polak P, Kim J, Hatanaka Y, Maejima K, Lawlor RT, Nakanishi Y, Mitsuhashi T, Fujimoto A, Furuta M, Ruzzenente A, Conci S, Oosawa A, Sasaki-Oku A, Nakano K, Tanaka H, Yamamoto Y, Michiaki K, Kawakami Y, Aikata H, Ueno M, Hayami S, Gotoh K, Ariizumi SI, Yamamoto M, Yamaue H, Chayama K, Miyano S, Getz G, Scarpa A, Hirano S, Nakamura T, Nakagawa H.
    J Hepatol; 2018 May 01; 68(5):959-969. PubMed ID: 29360550
    [Abstract] [Full Text] [Related]

  • 17. Management of biliary tract cancers in early-onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort.
    Lebeaud A, Antoun L, Paccard JR, Edeline J, Bourien H, Fares N, Tournigand C, Lecomte T, Tougeron D, Hautefeuille V, Viénot A, Henriques J, Williet N, Bachet JB, Smolenschi C, Hollebecque A, Macarulla T, Castet F, Malka D, Neuzillet C, Vernerey D, Boilève A, Turpin A.
    Liver Int; 2024 Aug 01; 44(8):1886-1899. PubMed ID: 38588031
    [Abstract] [Full Text] [Related]

  • 18. Biliary cancer: Utility of next-generation sequencing for clinical management.
    Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J.
    Cancer; 2016 Dec 15; 122(24):3838-3847. PubMed ID: 27622582
    [Abstract] [Full Text] [Related]

  • 19. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy.
    Uson Junior PLS, Majeed U, Yin J, Botrus G, Sonbol MB, Ahn DH, Starr JS, Jones JC, Babiker H, Inabinett SR, Wylie N, Boyle AWR, Bekaii-Saab TS, Gores GJ, Smoot R, Barrett M, Nagalo B, Meurice N, Elliott N, Petit J, Zhou Y, Arora M, Dumbauld C, Barro O, Baker A, Bogenberger J, Buetow K, Mansfield A, Mody K, Borad MJ.
    JCO Precis Oncol; 2022 Jun 15; 6(1):e2100274. PubMed ID: 35666960
    [Abstract] [Full Text] [Related]

  • 20. Alterations in DNA Damage Repair Genes in Primary Liver Cancer.
    Lin J, Shi J, Guo H, Yang X, Jiang Y, Long J, Bai Y, Wang D, Yang X, Wan X, Zhang L, Pan J, Hu K, Guan M, Huo L, Sang X, Wang K, Zhao H.
    Clin Cancer Res; 2019 Aug 01; 25(15):4701-4711. PubMed ID: 31068370
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.